|
SE8004580L
(sv)
*
|
1980-06-19 |
1981-12-20 |
Draco Ab |
Farmaceutisk beredning
|
|
SE8008524L
(sv)
*
|
1980-12-04 |
1982-06-05 |
Draco Ab |
4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
|
|
IT1196142B
(it)
*
|
1984-06-11 |
1988-11-10 |
Sicor Spa |
Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
|
|
SE8604059D0
(sv)
*
|
1986-09-25 |
1986-09-25 |
Astra Pharma Prod |
A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
|
|
LV5274A3
(lv)
*
|
1988-02-29 |
1993-10-10 |
Richter Gedeon Vegyeszet |
22(R,S)-11 beta,21-dihidroksi-16 alpha,17-butilidenbisoksipregna-1,4-dien-3,20-diona iegusanas panemiens
|
|
HU203769B
(en)
*
|
1989-03-09 |
1991-09-30 |
Richter Gedeon Vegyeszet |
Process for producing new steroide derivatives and pharmaceutical compositions containing them
|
|
SE8903219D0
(sv)
*
|
1989-10-02 |
1989-10-02 |
Astra Ab |
Process for the manufacture of budesonide
|
|
US5643602A
(en)
*
|
1989-11-22 |
1997-07-01 |
Astra Aktiebolag |
Oral composition for the treatment of inflammatory bowel disease
|
|
SE8903914D0
(sv)
|
1989-11-22 |
1989-11-22 |
Draco Ab |
Oral composition for the treatment of inflammatory bowel diseases
|
|
GR1001529B
(el)
*
|
1990-09-07 |
1994-03-31 |
Elmuquimica Farm Sl |
Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
|
|
US5888995A
(en)
*
|
1991-02-04 |
1999-03-30 |
Astra Aktiebolag |
Steroid esters
|
|
SE9100342D0
(sv)
*
|
1991-02-04 |
1991-02-04 |
Astra Ab |
Novel steroid esters
|
|
SE9100341D0
(sv)
*
|
1991-02-04 |
1991-02-04 |
Astra Ab |
Novel steroids
|
|
IE67345B1
(en)
*
|
1991-03-12 |
1996-03-20 |
Akzo Nv |
Low dose dry pharmaceutical preparations
|
|
FR2675146A1
(fr)
*
|
1991-04-10 |
1992-10-16 |
Roussel Uclaf |
Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires.
|
|
MD24C2
(ro)
*
|
1991-07-09 |
1994-05-31 |
Fabrica De Parfumerii Si Cosmetica "Viorica" |
Compoziţie de substanţe odorante
|
|
LT3695B
(en)
|
1991-11-18 |
1996-02-26 |
Dineika Raimundas Arnas |
Folded roof
|
|
CA2356145A1
(en)
*
|
1991-12-18 |
1993-06-24 |
Aktiebolaget Astra |
New combination of formoterol and budesonide
|
|
ATE154607T1
(de)
*
|
1992-12-24 |
1997-07-15 |
Rhone Poulenc Rorer Ltd |
Neue steroide
|
|
KR960700266A
(ko)
*
|
1993-01-08 |
1996-01-19 |
클래스 빌헬름슨 |
신규 결장- 또는 회장-특이성 스테로이드 유도체(Novel Colon-or lleum-Specific Steroid Derivatives)
|
|
GB9423919D0
(en)
*
|
1994-11-26 |
1995-01-11 |
Rhone Poulenc Rorer Ltd |
Chemical process
|
|
US6166024A
(en)
*
|
1995-03-30 |
2000-12-26 |
Mayo Foundation For Medical Education And Research |
Use of topical azathioprine and thioguanine to treat colorectal adenomas
|
|
FR2756739B1
(fr)
*
|
1996-12-05 |
2000-04-28 |
Astra Ab |
Nouvelle formulation de budesonide
|
|
IT1291288B1
(it)
|
1997-04-30 |
1999-01-07 |
Farmabios Srl |
Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
|
|
DE29717252U1
(de)
*
|
1997-09-26 |
1998-02-19 |
Falk Pharma Gmbh |
Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
|
|
US6266556B1
(en)
|
1998-04-27 |
2001-07-24 |
Beth Israel Deaconess Medical Center, Inc. |
Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
|
|
US6667299B1
(en)
*
|
2000-03-16 |
2003-12-23 |
Hollis-Eden Pharmaceuticals, Inc. |
Pharmaceutical compositions and treatment methods
|
|
HUP0200871A3
(en)
|
1999-05-04 |
2004-04-28 |
Strakan Int Ltd |
Androgen glycosides and androgenic activity thereof
|
|
GB0009583D0
(en)
*
|
2000-04-18 |
2000-06-07 |
Glaxo Group Ltd |
Respiratory formulations
|
|
GB0009613D0
(en)
*
|
2000-04-18 |
2000-06-07 |
Glaxo Group Ltd |
Pharmaceutical compositions
|
|
GB0009584D0
(en)
*
|
2000-04-18 |
2000-06-07 |
Glaxo Group Ltd |
Pharmaceutical compositions
|
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
|
US6667344B2
(en)
|
2001-04-17 |
2003-12-23 |
Dey, L.P. |
Bronchodilating compositions and methods
|
|
US20030055026A1
(en)
|
2001-04-17 |
2003-03-20 |
Dey L.P. |
Formoterol/steroid bronchodilating compositions and methods of use thereof
|
|
IL144900A
(en)
|
2001-08-14 |
2013-12-31 |
Neurim Pharma 1991 |
Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
|
|
AU2003291634A1
(en)
*
|
2002-10-08 |
2004-05-04 |
Sepracor Inc. |
Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
|
|
CA2522666A1
(en)
*
|
2003-04-18 |
2004-10-28 |
Pharmacia & Upjohn Company Llc |
Combination therapies for chronic obstructive pulmonary disease (copd)
|
|
TWI359675B
(en)
*
|
2003-07-10 |
2012-03-11 |
Dey L P |
Bronchodilating β-agonist compositions
|
|
AR045536A1
(es)
*
|
2003-08-29 |
2005-11-02 |
Ranbaxy Lab Ltd |
Inhibidores de la fosfodiesterasa tipo -iv
|
|
WO2005051931A2
(en)
*
|
2003-11-26 |
2005-06-09 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
|
EP1737861A4
(en)
|
2004-04-09 |
2010-04-28 |
Merck Sharp & Dohme |
INHIBITORS OF AKT ACTIVITY
|
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
|
ES2265276B1
(es)
|
2005-05-20 |
2008-02-01 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
|
TW200744612A
(en)
*
|
2005-08-26 |
2007-12-16 |
Astrazeneca Ab |
New combination
|
|
WO2007031838A1
(en)
|
2005-09-16 |
2007-03-22 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
|
CA2626612A1
(en)
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions of muscarinic receptor antagonists
|
|
WO2007045980A1
(en)
*
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type iv inhibitors
|
|
CA2622640A1
(en)
*
|
2005-11-02 |
2007-05-18 |
Sicor Inc. |
Improved process for the preparation of ciclesonide
|
|
AR059216A1
(es)
|
2006-01-27 |
2008-03-19 |
Sun Pharmaceutical Ind Ltd |
11b-hidroxiandrosta-4-eno-3-onas
|
|
US20070232578A1
(en)
*
|
2006-02-15 |
2007-10-04 |
Pierluigi Rossetto |
Crystalline forms of ciclesonide
|
|
ES2296516B1
(es)
*
|
2006-04-27 |
2009-04-01 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
|
EA016567B1
(ru)
|
2006-08-22 |
2012-05-30 |
Ранбакси Лабораториз Лимитед |
Ингибиторы матриксных металлопротеиназ
|
|
WO2008035316A2
(en)
*
|
2006-09-22 |
2008-03-27 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
|
WO2008035315A2
(en)
*
|
2006-09-22 |
2008-03-27 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type-iv
|
|
ES2302447B1
(es)
*
|
2006-10-20 |
2009-06-12 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
AU2007340129B2
(en)
|
2006-12-26 |
2012-02-02 |
Pharmacyclics Llc |
Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
|
|
SI2805945T1
(sl)
|
2007-01-10 |
2019-09-30 |
Msd Italia S.R.L. |
Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
|
|
GB0702456D0
(en)
|
2007-02-08 |
2007-03-21 |
Astrazeneca Ab |
New combination
|
|
ES2306595B1
(es)
*
|
2007-02-09 |
2009-09-11 |
Laboratorios Almirall S.A. |
Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
|
|
EP1958639A1
(en)
|
2007-02-14 |
2008-08-20 |
Polichem S.A. |
Use of chitosans for the treatment of nail inflammatory diseases
|
|
US10201490B2
(en)
|
2007-02-14 |
2019-02-12 |
Polichem Sa |
Use of chitosans for the treatment of nail inflammatory diseases
|
|
EP1958947A1
(en)
|
2007-02-15 |
2008-08-20 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type 4
|
|
CN103497185A
(zh)
|
2007-03-14 |
2014-01-08 |
兰贝克赛实验室有限公司 |
用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
|
|
EP2124943A1
(en)
*
|
2007-03-14 |
2009-12-02 |
Ranbaxy Laboratories Limited |
Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
|
|
WO2009002495A1
(en)
|
2007-06-27 |
2008-12-31 |
Merck & Co., Inc. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
US20090082319A1
(en)
*
|
2007-09-25 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched budesonide
|
|
WO2009045539A2
(en)
|
2007-10-05 |
2009-04-09 |
Nektar Therapeutics Al, Corporation |
Oligomer-corticosteroid conjugates
|
|
ES2320961B1
(es)
*
|
2007-11-28 |
2010-03-17 |
Laboratorios Almirall, S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
|
|
EP2096105A1
(en)
*
|
2008-02-28 |
2009-09-02 |
Laboratorios Almirall, S.A. |
Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
|
|
PT2262823E
(pt)
*
|
2008-03-13 |
2013-03-05 |
Farmabios Spa |
Processo para a preparação de derivados de pregnano
|
|
ITMI20080645A1
(it)
|
2008-04-11 |
2009-10-12 |
Ind Chimica Srl |
Procedimento per la preparazione di budesonide
|
|
EP2111861A1
(en)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
|
CN101279997B
(zh)
*
|
2008-05-29 |
2011-08-24 |
鲁南制药集团股份有限公司 |
布地奈德的一种制备方法
|
|
UY32297A
(es)
|
2008-12-22 |
2010-05-31 |
Almirall Sa |
Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
|
|
GB0900484D0
(en)
|
2009-01-13 |
2009-02-11 |
Angeletti P Ist Richerche Bio |
Therapeutic agent
|
|
EP2228368A1
(en)
|
2009-03-12 |
2010-09-15 |
Almirall, S.A. |
Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
|
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
|
US8603521B2
(en)
|
2009-04-17 |
2013-12-10 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor and uses thereof
|
|
US8815258B2
(en)
|
2009-05-29 |
2014-08-26 |
Pearl Therapeutics, Inc. |
Compositions, methods and systems for respiratory delivery of two or more active agents
|
|
CA2763939A1
(en)
|
2009-05-29 |
2010-12-02 |
Pearl Therapeutics, Inc. |
Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
|
|
GB0916608D0
(en)
|
2009-09-22 |
2009-11-04 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
SG10201912526TA
(en)
|
2009-10-01 |
2020-02-27 |
Adare Pharmaceuticals Inc |
Orally administered corticosteroid compositions
|
|
WO2011046771A1
(en)
|
2009-10-14 |
2011-04-21 |
Schering Corporation |
SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
|
|
WO2011073662A1
(en)
|
2009-12-17 |
2011-06-23 |
Astrazeneca Ab |
Combination of a benzoxazinone and a further agent for treating respiratory diseases
|
|
WO2011093812A2
(en)
|
2010-01-28 |
2011-08-04 |
Mahmut Bilgic |
Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
|
|
WO2011097594A2
(en)
|
2010-02-08 |
2011-08-11 |
Kinagen, Inc. |
Therapeutic methods and compositions involving allosteric kinase inhibition
|
|
CN101863952B
(zh)
*
|
2010-04-30 |
2013-04-17 |
湖北葛店人福药业有限责任公司 |
布地奈德的制备方法
|
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
|
WO2012018754A2
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP3587574B1
(en)
|
2010-08-17 |
2022-03-16 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
|
EP2632472B1
(en)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
WO2012145471A1
(en)
|
2011-04-21 |
2012-10-26 |
Merck Sharp & Dohme Corp. |
Insulin-like growth factor-1 receptor inhibitors
|
|
RU2609833C2
(ru)
|
2011-09-13 |
2017-02-06 |
Фармасайкликс Элэлси |
Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
|
|
EP2578570A1
(en)
|
2011-10-07 |
2013-04-10 |
Almirall, S.A. |
Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
|
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
|
WO2013109214A1
(en)
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Process for the preparation of dry powder formulations
|
|
EP2641900A1
(en)
|
2012-03-20 |
2013-09-25 |
Almirall, S.A. |
Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
|
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
|
CN103421075B
(zh)
*
|
2012-05-16 |
2017-07-28 |
上海特化医药科技有限公司 |
孕烷衍生物16,17‑缩醛(酮)的制备方法
|
|
US20150165037A1
(en)
|
2012-07-05 |
2015-06-18 |
Arven llac Sanayi Ve Ticaret A.S. |
Inhalation compositions comprising corticosteroid and sorbitol
|
|
WO2014007781A2
(en)
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Inhalation compositions
|
|
US10105316B2
(en)
|
2012-07-05 |
2018-10-23 |
Arven llac Sanayi Ve Ticaret A.S. |
Inhalation compositions comprising muscarinic receptor antagonist
|
|
US10111957B2
(en)
|
2012-07-05 |
2018-10-30 |
Arven Ilac Snayi ve Ticaret A.S. |
Inhalation compositions comprising glucose anhydrous
|
|
BR112015003729A2
(pt)
|
2012-08-24 |
2018-06-05 |
Univ Texas |
composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
|
|
US9233979B2
(en)
|
2012-09-28 |
2016-01-12 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
|
PL2925888T3
(pl)
|
2012-11-28 |
2018-03-30 |
Merck Sharp & Dohme Corp. |
Kompozycje i sposoby do stosowania w leczeniu nowotworów
|
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
KR102391332B1
(ko)
|
2013-03-15 |
2022-04-26 |
펄 테라퓨틱스 인코포레이티드 |
미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
|
|
SG11201509543YA
(en)
|
2013-05-22 |
2015-12-30 |
Pearl Therapeutics Inc |
Compositions, methods & systems for respiratory delivery of three or more active agents
|
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
WO2015034678A2
(en)
|
2013-09-06 |
2015-03-12 |
Aptalis Pharmatech, Inc. |
Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
|
|
CA2936748C
(en)
|
2014-10-31 |
2017-08-08 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
|
EP3250211B1
(en)
|
2015-01-30 |
2021-12-22 |
Coral Drugs Pvt. Ltd. |
Novel process for preparation of glucocorticoid steroids
|
|
EP3475275B1
(en)
|
2016-06-23 |
2024-04-10 |
Merck Sharp & Dohme LLC |
3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
|
|
TWI728172B
(zh)
|
2016-08-18 |
2021-05-21 |
美商愛戴爾製藥股份有限公司 |
治療嗜伊紅性食道炎之方法
|
|
JP7330101B2
(ja)
|
2016-11-08 |
2023-08-21 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
ステロイド及びそのタンパク質コンジュゲート
|
|
CN110944718A
(zh)
|
2017-05-18 |
2020-03-31 |
里珍纳龙药品有限公司 |
环糊精蛋白质药物偶联物
|
|
BR112020022400A2
(pt)
|
2018-05-09 |
2021-02-02 |
Regeneron Pharmaceuticals, Inc. |
anticorpos anti-msr1 e métodos de uso dos mesmos
|
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
|
CA3160153A1
(en)
|
2019-12-17 |
2021-06-24 |
Michelle Machacek |
Prmt5 inhibitors
|
|
IL309888A
(en)
|
2021-07-09 |
2024-03-01 |
Astrazeneca Pharmaceuticals Lp |
Aerosol drug delivery compounds, methods and systems
|
|
WO2023119093A1
(en)
|
2021-12-20 |
2023-06-29 |
Astrazeneca Ab |
Compositions, methods and systems for aerosol drug delivery
|
|
WO2024049931A1
(en)
|
2022-09-02 |
2024-03-07 |
Merck Sharp & Dohme Llc |
Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
|
|
WO2024091437A1
(en)
|
2022-10-25 |
2024-05-02 |
Merck Sharp & Dohme Llc |
Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
|
